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SUMMARY
We have studied postoperative analgesia and
unwanted side effects of a single dose of a mixture
of morphine and sufentanil administered extra -
durally with the effects produced by extradural
injection of each opioid alone in 64 patients after
Caesarean delivery. The patients were allocated
randomly to receive morphine 4 mg (n = 21),
sufentanil 50 ng (n = 22) or morphine 2 mg with
sufentanil 25 /xg (n = 21) via an extradural catheter
in a double-blind design. Intensity of pain was
measured using a linear visual analogue scale.
Compared with the effect produced by morphine
alone, the morphine-sufentanil combination pro-
duced more rapid onset of pain relief (19 (SD 5)
min vs 79 (23) min for a 75% reduction of pain;
P < 0.01), whereas the duration and quality of
analgesia assessed during 12 h was similar for these
two groups. In contrast, patients receiving
sufentanil alone required significantly more sup-
plementary analgesia 4 h after administration than
with morphine alone or morphine combined with
sufentanil. There were no significant changes
in cardiorespiratory variables in any group. Side
effects consisted mainly of pruritus and nausea and
did not differ between groups, with the exception
of early and transient dizziness which was observed
only in patients given sufentanil either alone or in
combination with morphine. We conclude that a
single extradural injection of morphine and
sufentanil combines the short onset time produced
by sufentanil and the long duration of analgesia
attributable to morphine, thus providing excellent
and prolonged analgesia after Caesarean delivery.
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Continuous administration of opioids via an extra-
dural catheter is being used increasingly for analgesia
after Caesarean section. Morphine remains the
reference substance among the agents used in this
situation [1-4]. While the quality of analgesia with
this opioid is excellent, the onset of pain reduction,
which ranges from 45 to 90 min, is late, thus usually
necessitating concomitant parenteral injection of
another opioid. Unwanted side effects of extradural
morphine include nausea, vomiting, pruritus, ex-
cessive sedation, urinary retention and early or
delayed respiratory depression. These problems
limit the widespread routine use of this mode of
administration. In particular, reports of delayed,
profound and prolonged respiratory depression
impose the need for continuous surveillance over
many hours after extradural morphine has been
administered [5-9].
Sufentanil is a lipophilic opioid belonging to the
fentanyl derivatives, with physicochemical and
pharmacodynamic characteristics distinct from those
of morphine derivatives. It is five to seven times
more potent than fentanyl, highly lipophilic, and has
a high affinity for spinal cord mu opioid receptors.
As a result, sufentanil possesses a rapid onset of
action with excellent analgesic properties [10].
However, the duration of action of sufentanil
administered by the extradural route is less than 4 h
[10-12]. Adequate postoperative analgesia with this
drug therefore requires either continuous
administration or repeated i.v. bolus injections.
Because of their different pharmacokinetic and
pharmacodynamic characteristics, administration of
morphine and sufentanil as a single combined
injection via an extradural catheter at 50 % of the
dose used for each agent alone should allow ad-
vantageous combination of the short onset time of
sufentanil and the long duration of analgesia of
morphine. In addition, it may be possible to reduce
the incidence of side effects observed with each
agent alone.
The present study was undertaken to evaluate,
after Caesarean delivery, the time course of post-
operative analgesia using a mixture of morphine and
sufentanil injected extradurally. In addition, we
wished to compare the observed effects of this
combination with those produced by extradural
injection of each opioid alone.
PATIENTS AND METHODS
Sixty-four ASA I or II patients undergoing elective
Caesarean delivery gave informed consent to par-
ticipate to the study, which was approved by the
Ethics Committee for Human Research of our
institution. Drug-dependent patients or those who
had received parenteral injection of a benzodiazepine
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or an analgesic in the postoperative period were
excluded. No medication was administered to the
parturient during the study, other than the two
opioids investigated, the local anaesthetics used for
delivery by Caesarean section, and ephedrine ad-
ministered when there was a decrease in mean
arterial pressure of more than 25 % of baseline.
Before operation, a large i.v. cannula was inserted
into a peripheral arm vein and patients received
balanced electrolyte solution lOmlkg'1. An
extradural catheter was introduced at the L2-3 or
L3-4 interspace and advanced 5 cm cephalad. A
mixture of equal volumes of 0.5 % bupivacaine and
2 % lignocaine was injected in incremental doses into
the extradural space to produce a sensory anaesthesia
to T4 dermatome. In addition, the bladder was
catheterized.
After delivery of the infant, the patient was
transferred to the recovery room. When the patient
first requested pain relief she was asked to rate her
level of pain intensity on a 10-cm linear visual
analogue scale (VAS) (0 = no pain; 10 = worst pain)
[13, 14]. Baseline arterial pressure, heart rate and
ventilatory frequency were noted. The anaesthetist
then injected through the extradural catheter in a
randomized and double-blind manner one of three
preparations: group 1 = sufentanil 50 ug; group
2 = morphine 4 mg; group 3 = sufentanil 25 ug
+ morphine 2 mg. Each preparation consisted of two
syringes (in order to avoid mixing morphine and
sufentanil) with the opioid diluted in 0.9% sodium
chloride 5 ml, to produce a total injected volume of
10 ml. The original blinded vials containing the
drugs were prepared and provided by Janssen
Pharmaceuticals.
After the extradural injection of the opioid, the
following variables were recorded, first at 5-min
intervals during the first 15 min, then every 15 min
during the subsequent 2 h and then at 1 -h intervals
to the end of the study (12 h): pain intensity as
estimated by VAS score; heart rate and rhythm
using a standard Hewlett-Packard monitor; mean
arterial pressure using a non-invasive automatic
pressure monitor (Dinamap, Criticon, U.S.A.);
ventilatory frequency by counting ventilations; and
oxygen haemoglobin saturation by pulse oximetry
(Satlite, Datex Instrumentarium, Helsinki, Finland).
Side effects such as pruritus, nausea, vomiting,
drowsiness and respiratory depression were recorded
during the investigation by the nursing staff. If
necessary, these side effects were treated with
promethazine (pruritus), metoclopramide (nausea
and vomiting) or naloxone (respiratory depression).
The patients remained in the recovery room for at
least 12 h after the first extradural injection of opioid.
They were instructed to ask for additional parenteral
pain medication (morphine, pethidine) when they
began to experience pain and the time interval
between extradural and parenteral administration of
opioid was recorded.
Statistical analysts
Numeric data were expressed as means (SD) and
compared between groups with one-way analysis
of variance followed by Student's t test using
Bonferroni's correction. Non-parametric data were
compared using chi-square analysis. The mean time
interval in each treatment group corresponding to a
decrease of the VAS pain score to 50 % or 25 % of
baseline, respectively, was obtained by linear re-
gression analysis of individual VAS scores over the
initial time period.
RESULTS
There were no significant differences between the
three groups of patients in the number of parturients
entered in each group, age, height, weight or parity
(table I).
Time to the onset of pain relief was similar in the
sufentanil and morphine-sufentanil groups, but
statistically longer in the morphine group (fig. 1). A
50% decrease in pain score from baseline was
observed within 7 (0.2) min in the sufentanil group
and within 13 (3) min in the morphine-sufentanil
group, but was not observed until 53 (15) min after
morphine administration (P < 0.01 compared with
the other two groups). Similarly, a 75 % reduction in
pain score was observed after 10 (0.3) min in the
sufentanil group, 19 (5) min in the morphine-
sufentanil group and 79 (23) min in the morphine
group (P < 0.01).
From 60 min after extradural drug injection until
the end of the 12-h study, the VAS score was no
longer significantly different between patients who
received morphine and those who received the
morphine—sufentanil combination. In patients given
sufentanil alone, the VAS score was smaller at first
TABLE I. Pattern data (mean (SD)). NO statistically significant
differences between groups
Sufentanil Morphine Morphine-sufentanil
(n = 22) (n = 21) (n = 21)
Weight (kg)
Height (cm)
Age(yr)
76(12)
160(5)
31
71(11)
161 (7)
30 (20-^11)
70(11)
158 (6)
32 (24-^12)
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FIG. 1. Pain, as measured by visual analogue scale (VAS), before
and after the first 120 min of extradural administration of
morphine 4 mg (O) (" = 21), sufentanil 50 ug ( • ) (n = 22) or the
combination of morphine 2 mg and sufentanil 25 ug (A) (n = 21)
(mean + SE). *P < 0.05 compared with time-matched data points
for morphine administration.
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FIG. 2. Pain, as measured by visual analogue scale (VAS), before
and after extradural administration of morphine 4 mg (O)
(n = 21), sufentanil 50 ug ( • ) (n = 22) or the combination of
morphine 2 mg and sufentanil 25 ug (A) (n = 21) (mean + SE).
*P < 0.05 compared with time-matched data points for morphine
administration.
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FIG. 3. Number of patients (expressed as percentage of patients of
each group) requiring supplementary analgesia after a single
extradural administration of morphine 4 mg ( S ) (n = 21),
sufentanil 50 ug ( • ) (n = 22) or the combination of morphine
2 mg and sufentanil 25 ug (D) (" = 21). **P < 0.01 compared
with time-matched data points for morphine administration.
TABLE II. Respiratory variables (mean (SD) [range]) and patients
(No. (%)) with side effects after extradural sufentanil, morphine
or moTphine-sufentanil combination. *P < 0.05 compared with
morphine
Ventilatory frequency
(b.p.m.)
O, haemoglobin
saturation (%)
Pruritus
Nausea or vomiting
Dizziness
Sufentanil
(n = 22)
17.1 (2.2)
[9-24]
96.0(1.4)
[90-100]
9(41)
3(14)
3(14)*
Morphine
(n = 21)
18.5 (3.2)
[10-28]
96.7(1.2)
[92-99]
10(48)
2(10)
0(0)
Morphine-
sufentanil
(n = 21)
17.1(1.9)
[12-24]
96.5(1.2)
[91-99]
9(43)
2(10)
6(29)*
(between 75 and 105 min) (fig. 1); thereafter it was
significantly greater (between 4 and 11 h) than in the
two other groups (fig. 2).
The need for supplementary analgesia appeared at
105 min in the sufentanil group and became and
remained significantly different from that in the
other two groups between 6 and 12 h of the study
(fig. 3). There were no significant differences be-
tween the two other groups in this respect. At 12 h,
77% of patients in the sufentanil group had
requested additional pain medication, whereas only
24% (morphine-sufentanil group) and 19% (mor-
phine group) requested analgesia in the other two
groups.
Heart rate and mean arterial pressure were similar
in the three groups and did not change significantly
in any group. Similarly, ventilatory frequency and
oxygen haemoglobin saturation were unchanged
during the whole study; the slowest ventilatory
frequency (9 b.p.m.) was noted in one patient at
30 min, associated with an oxygen haemoglobin
saturation of 90% and was not accompanied by
clinical signs of respiratory depression (table II).
Pruritus and nausea or vomiting were observed in
similar proportions in all three groups (table II),
with 25 % (sufentanil-morphine group) to 50 %
(morphine group) of patients requiring treatment
with either promethazine or metoclopramide. Diz-
ziness was present in 14% of parturients in the
sufentanil group and in 28% of the sufentanil-
morphine group, but was absent in all patients
receiving morphine alone (table II). This side effect
was rated mild by the parturients, lasted only a few
minutes, and had disappeared completely within
30 min of injection, without treatment.
After the 12-h follow-up study, the patients
remained under close monitoring, including pulse
oximetry and frequent observation by the ward
nurses. There were no complications during the
subsequent 12 h.
DISCUSSION
Extradural morphine or sufentanil has been reported
to be effective for post-Caesarean pain control [1-4,
10-12]. Our results with both morphine or sufentanil
alone confirm previous studies. With morphine, the
quality of analgesia was judged excellent and lasted
at least 12 h. Side effects consisted mainly of pruritus
(47%) and nausea (9%); there was no clinically
significant decrease in ventilatory frequency or
oxygen haemoglobin saturation. In contrast, extra-
dural injection of sufentanil 50 ug produced very
rapid pain relief that was effective but of short
duration (~ 4 h), while producing an identical
incidence of side effects. Fourteen per cent of
patients in this group also presented some degree of
mild dizziness which disappeared spontaneously
within 15 min. This has been reported also by
Klepper and colleagues in human volunteers [15],
whereas others did not report this side effect [10-12].
Injection of a combination of these two opioids at
50 % of the dose used alone (morphine 2 mg,
sufentanil 25 ng) produced rapid onset of analgesia
(within 19 min), of excellent quality, and of pro-
longed duration (> 12 h). During the first minutes,
the quality and onset time of pain relief were
comparable to those observed with sufentanil alone,
and over the 12 h studied the quality and duration of
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analgesia were comparable to that observed with
morphine administration. Furthermore, the need for
supplementary analgesics did not differ between
patients receiving the sufentanil-morphine com-
bination and those given morphine alone (24 % and
19%, respectively).
The doses of morphine used in this combination
have been reported to be insufficient as a single dose
[2, 16]. In the present study, we were able to show
that this dose was nevertheless sufficient for pro-
longed analgesia when combined with sufentanil.
These results indicate further that competition at
spinal cord mu opioid receptors did not seem to
occur, and effects were sequential and partly ad1
ditive. This mode of opioid administration allowed
reduction in the amount of opioid injected into the
extradural space, thus reducing the incidence of
possible side effects caused by excess morphine in
the cerebrospinal fluid. The greater lipophilicity of
sufentanil provided rapid diffusion of the drug into
the cerebrospinal space, where it is bound very
strongly to mu opioid receptors [17]. The com-
bination of these two properties, lipid solubility and
affinity for mu receptors, explains its rapid and
potent analgesic effect. In contrast, the more hydro-
philic morphine diffuses more slowly into the
intrathecal space, which accounts for its delayed
onset but prolonged duration of action [18]. With the
exception of dizziness, which was noted only in
presence of sufentanil, either alone or in combination
with morphine, the other classical side effects noted
with opioids were similar in the three groups,
indicating that, in spite of the reduced amount of
each opioid alone, their combination in a single
injection did not significantly diminish the incidence
of side effects produced by each drug separately. The
transient sensation of dizziness may possibly be
explained by sufentanil reaching the equilibrium
centres in the central nervous system via diffusion
into the intravascular space.
Haemodynamic and respiratory variables did not
change significantly in the groups. However, our
results do not exclude subclinical respiratory de-
pression. Ventilatory response to carbon dioxide was
not measured in this study, and the relatively small
number of patients in each group is insufficient to
evaluate a complication that has an incidence of
0.09-0.90% [9, 16]. Nevertheless, it is likely that the
risk of delayed respiratory depression is attenuated
with this mode of combined opioid administration,
as this potentially disastrous complication appears to
occur most frequently with poorly lipid-soluble
drugs, such as morphine [19]. 1
In summary, we have demonstrated that the
simultaneous injection of sufentanil and morphine
into the extradural space for postoperative analgesia
after Caesarean delivery combined the advantages of
both drugs administered alone—rapid onset of action
produced by sufentanil, together with a long dur-
ation of action produced by morphine.
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